TITLE

Immunex/AHP effort touts 'Enbrel effect.'

AUTHOR(S)
Goetzl, David
PUB. DATE
May 1999
SOURCE
Advertising Age;5/3/1999, Vol. 70 Issue 19, p58
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that Immunex Corp. will launch a national print advertising campaign in May 1999 for its rheumatoid arthritis drug Enbrel. Where the advertising will be seen; Approval Enbrel received from the United States Food & Drug Administration in November 1998; Statistics on the sales of Enbrel through the first quarter of 1999.
ACCESSION #
1838577

 

Related Articles

  • Infections, Deaths Prompt Arthritis Drug Label Change.  // FDA Consumer;Jul/Aug99, Vol. 33 Issue 4, p2 

    Reports on the label change in the rheumatoid arthritis drug Enbrel in response to six deaths and other serious infections in patients taking the drug. Recommendations included in the label of the drug; Action taken by drug marketer Immunex Corp. on the issue; Requirements of the United States...

  • New arthritis drugs approved, face age-old marketing pains.  // Medical Marketing & Media;Dec98, Vol. 33 Issue 12, p14 

    Reports that Immunex has received approval from the United States Food and Drug Administration (FDA) for Enbrel, the first tumor necrosis factor drug for severe rheumatoid arthritis (RA). Amount to be invested by Immunex, its majority stock holder and co-marketing partner American Home Products...

  • Warning issued on RA drug. Maudlin, Robert K. // Modern Medicine;Jun99, Vol. 67 Issue 6, p51 

    Focuses on the advice of the United States Food and Drug Administration regarding the use of etanercept, an approved treatment for moderate to severe rheumatoid arthritis. Warning on the label when the drug was originally approved; Advice for physicians when considering prescribing etanercept...

  • Rheumatoid arthritis drugs show promise.  // Mayo Clinic Health Letter;Jan1999, Vol. 17 Issue 1, p4 

    Broadcasts the approval of the Food and Drug Administration for two drugs, etanercept and leflunomide for the treatment of rheumatoid arthritis. Drug composition; Dosage.

  • Dateline Washington. Coorsh, Richard // Consumers' Research Magazine;Dec98, Vol. 81 Issue 12, p6 

    Introduces Enbrel, a genetically engineered drug approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis.

  • Hitting RA head-on. Portyansky, Elena // Drug Topics;9/7/98, Vol. 142 Issue 17, p21 

    Reports that the disease-modifying antiheumatic drug (DMARD), Arava (leflunomide), for treatment of active rheumatoid arthritis (RA) in adults has been recommended for approval by a Food and Drug Administration advisory committee in the United States. Benefits of the drug; Uses of the drug if...

  • FDA approves rheumatoid arthritis drug.  // Dermatology Times;Jan2002, Vol. 23 Issue 1, p14 

    Announces that the United States Food and Drug Administration has given its approval for anakinra, a drug for the treatment of rheumatoid arthritis for patients who have failed one or more disease-modifying antirheumatic drugs. Drug background.

  • New Treatment Device for Rheumatoid Arthritis. Rose, Verna L. // American Family Physician;5/1/1999, Vol. 59 Issue 9, p2656 

    Reports that the United States Food and Drug Administration has approved Prosorba, a therapeutic device for patients with rheumatoid arthritis. How the device works; Results from clinical trials.

  • Immunex files for generic Taxol. Tilton, Helga // Chemical Market Reporter;12/08/97, Vol. 252 Issue 23, p15 

    Reports on the patent application made by Immunex Corp. to the Food and Drug Administration (FDA) for the paclitaxel injection or Taxol. Indication of the drug; Incentive for successful patent challenge.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics